Corporate
2021.02.01
LT3001 Compound Patent Approved in Korea and Europe
Patents Approved in South Korea and European Countries for Lumosa's Novel Treatment for Acute Ischemic Stroke
Encouraging Global Patent Position and Advancements in Clinical Studies
(February 1, 2021; Taipei) Lumosa Therapeutics (Lumosa; 6535.TWO) announced today (February 1) the granting of the chemical compound patent for its LT3001, a potential blockbuster novel treatment for acute ischemic stroke, by the European and Korean patent offices. This patent will provide protection until June of 2034. Lumosa will proceed with the national validation in 38 member states of the European Patent Convention (EPC), including Germany, the United Kingdom, France, Italy, Switzerland, and Austria. So far, LT3001 compound patent has been granted in 14 regions, including Taiwan, the United States, China, Japan, Australia, Russia, Europe, and South Korea. In addition, similar patent applications are being reviewed in 4 additional countries.
According to GlobalData, the number of global acute ischemic stroke patients continue to increase at a rate of 2.74% per year. By 2027, the number of patients would reach 23 million. Lumosa’s LT3001 has the potential of addressing the urgent medical needs and becoming a blockbuster .
Lumosa has completed the enrollment of a Phase 2 single-dose clinical study in patients in Taiwan and the United States and data is expected in the 2021Q2. In addition, Lumosa and its Chinese partner will carry out Phase 1 multiple-dose studies in healthy volunteers in the United States and China, respectively. The data could help finding the optimum dosing regiments of LT3001 in stroke treatment. Subsequently, Lumosa plans to initiate a Phase 2 multiple-dose study combing thrombectomy in patients in the second half of this year.
Encouraging Global Patent Position and Advancements in Clinical Studies
(February 1, 2021; Taipei) Lumosa Therapeutics (Lumosa; 6535.TWO) announced today (February 1) the granting of the chemical compound patent for its LT3001, a potential blockbuster novel treatment for acute ischemic stroke, by the European and Korean patent offices. This patent will provide protection until June of 2034. Lumosa will proceed with the national validation in 38 member states of the European Patent Convention (EPC), including Germany, the United Kingdom, France, Italy, Switzerland, and Austria. So far, LT3001 compound patent has been granted in 14 regions, including Taiwan, the United States, China, Japan, Australia, Russia, Europe, and South Korea. In addition, similar patent applications are being reviewed in 4 additional countries.
According to GlobalData, the number of global acute ischemic stroke patients continue to increase at a rate of 2.74% per year. By 2027, the number of patients would reach 23 million. Lumosa’s LT3001 has the potential of addressing the urgent medical needs and becoming a blockbuster .
Lumosa has completed the enrollment of a Phase 2 single-dose clinical study in patients in Taiwan and the United States and data is expected in the 2021Q2. In addition, Lumosa and its Chinese partner will carry out Phase 1 multiple-dose studies in healthy volunteers in the United States and China, respectively. The data could help finding the optimum dosing regiments of LT3001 in stroke treatment. Subsequently, Lumosa plans to initiate a Phase 2 multiple-dose study combing thrombectomy in patients in the second half of this year.
